A Phase 3 interventional study of Placebo and Abiraterone acetate in Prostatic Neoplasms, sponsored by Cougar Biotechnology, Inc.. Completed at 128 sites in 12 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-04-30.
Sponsored by Cougar Biotechnology, Inc. (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 98 studies testing Abiraterone Acetate in Prostatic Neoplasms — 12 open to participants now, 29 under way, 4 of them phase 3. Abiraterone Acetate · Prostatic Neoplasms.
Among the 98 studies testing Abiraterone Acetate in Prostatic Neoplasms, this one is the 3rd largest by enrollment, is the only one that started in 2008, is one of 11 in phase 3, and was the 7th registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →12 of the 98 studies testing Abiraterone Acetate in Prostatic Neoplasms are open now, in 8 countries. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18+ · Men only
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Sites in United States
Ages 18+ · Men only
Alliance for Clinical Trials in Oncology · Sites in United States
Ages 18+
VA Office of Research and Development · Sites in United States
Ages 18+ · Men only
Deventer Ziekenhuis · Sites in Netherlands
Ages 18+ · Men only
By country, each count listing its studies:
Abiraterone Acetate: first FDA approval 2011 (ZYTIGA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
98 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 67 · Phase 3 11 · Phase 4 4
First in 2005; this study’s year is marked. 1 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,195 is above the median of 60 across 5,352 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 56 across the 98 interventional studies. Of the 60 that completed or were terminated, 40 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 98 have an industry lead sponsor. The 10 most frequent:
This study is registered under Cougar Biotechnology, Inc., one of the names counted as Johnson & Johnson. Under that name alone:
Cougar Biotechnology, Inc. is the lead sponsor of 12 studies on the registry; none are open to participants now.
88 studies in Prostatic Neoplasms by Johnson & Johnson: 9 open now, 23 under way, 9 of them phase 3. Of 58 finished, 24 (41%) have results posted.
Among the 88 studies in Prostatic Neoplasms by Johnson & Johnson, this one is the 5th largest by enrollment of the 68 interventional ones that give a count, is the only one that started in 2008, is one of 15 in phase 3, and was the 12th registered.
Johnson & Johnson’s Prostatic Neoplasms studies by the year they started, since 1995.
8 of the studies testing Abiraterone Acetate in Prostatic Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03903835Phase 3Karolinska InstitutetProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer | 2026-12 |
| NCT05406999The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNeoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer | 2026-12-31 |
| NCT03902951Jonsson Comprehensive Cancer CenterAntiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer | 2027-01-01 |
| NCT01786265M.D. Anderson Cancer CenterFinite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer | 2027-02-01 |
| NCT04194554University of Michigan Rogel Cancer CenterA Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer | 2027-05 |
Add all 8 to your calendar (.ics) → With an account.
Among the 98 studies testing Abiraterone Acetate in Prostatic Neoplasms, from their registry updates:
Among Johnson & Johnson’s 88 in Prostatic Neoplasms:
This tab as a report to print or save as PDF → With an account.
This is a phase 3 study to compare the clinical benefit of abiraterone acetate plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer (CRPC) who have failed one or two chemotherapy regimens. At least one of the previous chemotherapies must have contained docetaxel.
Abiraterone acetate is a steroidal irreversible inhibitor of CYP17 (17α hydroxylase/C17, 20-lyase), blocking 2 important enzymatic activities in the synthesis of testosterone. The goal of this study is to compare the clinical benefit of abiraterone acetate plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer (CRPC) who have failed one or two chemotherapy regimens, one of which contains docetaxel. All patients involved in the study will be randomized (assigned by chance) into one of two arms and will not know what study drug is being given to them. Study drug randomization allocation will be 2:1 (abiraterone acetate: placebo). The study will be conducted in the United States, Canada, Australia, and the EU. The study will consist of screening, treatment, and follow-up. In this study, patients will receive study treatment (abiraterone acetate or placebo) plus prednisone until progression of clinical disease. Follow-up will continue until patient dies, is lost to follow-up, or withdraws informed consent. After providing written informed consent, patients will have screening procedures completed to determine eligibility. Safety evaluations at the screening procedure will include a physical examination, vital signs, and clinical blood laboratory tests, ECG, radiographs, urine tests, and recording of any adverse events including details of current prostate cancer symptoms. Patients will be asked to use a method of birth control with adequate barrier protection as determined to be acceptable by the principal investigator and sponsor during the study and for 13 weeks after last study drug administration.
Study medication, abiraterone acetate,is an oral (by mouth) medication to be administered as four (4) 250mg abiraterone acetate tablets or 4 placebo tablets to be taken at least one hour before or two hours after a meal anytime up to 10PM everyday. Prednisone will be administered as 5mg orally twice a day for both groups. Each cycle will be 28 days. Study treatment will continue until disease progression as determined by investigator or when the patient meets criteria for withdrawal from study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Abiraterone acetate · Drug: Prednisone/prednisolone
Drug: Placebo · Drug: Prednisone/prednisolone
Four tablets once daily until disease progression
Four 250-mg tablets once daily until disease progression
Drug pages: Prednisone · Prednisolone
5 mg twice daily until disease progression
Overall Survival
Overall survival is defined as the time interval from the date of randomization to the date of death from any cause.
Time frame: Up to 60 months
Time to Prostate-Specific Antigen Progression According to Prostate Specific Antigen Working Group Criteria
The time interval from the date of randomization to the date of the prostate-specific antigen (PSA) progression as defined in the protocol-specific Prostate Specific Antigen Working Group (PSAWG) criteria, namely, a PSA level of at least 5 ng/ml that has risen on at least 2 successive occasions, at least 2 weeks apart.
Time frame: Up to 12 months
Number of Patients Achieving a Prostate-Specific Antigen Decline >=50%
A prostate-specific antigen (PSA) response was defined as a \>=50% decline from baseline.
Time frame: Up to 12 months
Radiographic Progression-free Survival
Radiographic progression-free survival is based on imaging studies according to modified Response Evaluation Criteria in Solid Tumors (RECIST): baseline lymph node size must be \>=2.0 cm to be considered a target lesion; progression on bone scans with \>=2 new lesions not consistent with tumor flare, confirmed on a second scan \>=6 weeks later that shows \>=1 additional new lesion.
Time frame: Up to 11 months
| Milestone | Abiraterone Acetate | Placebo |
|---|---|---|
| Started | 797 | 398 |
| Completed | 116 | 56 |
| Not completed | 681 | 342 |
| Withdrew: Death | 655 | 335 |
| Withdrew: Withdrawal by subject | 22 | 5 |
| Withdrew: Lost to follow-up | 4 | 2 |
Overall survival is defined as the time interval from the date of randomization to the date of death from any cause.
| Days | Abiraterone Acetate | Placebo |
|---|---|---|
| Overall Survival | 450.0 (430.0 to 470.0) | 332.0 (310.0 to 366.0) |
The time interval from the date of randomization to the date of the prostate-specific antigen (PSA) progression as defined in the protocol-specific Prostate Specific Antigen Working Group (PSAWG) criteria, namely, a PSA level of at least 5 ng/ml that has risen on at least 2 successive occasions, at least 2 weeks apart.
| Days | Abiraterone Acetate | Placebo |
|---|---|---|
| Time to Prostate-Specific Antigen Progression According to Prostate Specific Antigen Working Group Criteria | 309.0 (255.0 to 421.0) | 200.0 (170.0 to 254.0) |
A prostate-specific antigen (PSA) response was defined as a \>=50% decline from baseline.
| Participants | Abiraterone Acetate | Placebo |
|---|---|---|
| Number of Patients Achieving a Prostate-Specific Antigen Decline >=50% | 232 | 22 |
Radiographic progression-free survival is based on imaging studies according to modified Response Evaluation Criteria in Solid Tumors (RECIST): baseline lymph node size must be \>=2.0 cm to be considered a target lesion; progression on bone scans with \>=2 new lesions not consistent with tumor flare, confirmed on a second scan \>=6 weeks later that shows \>=1 additional new lesion.
| Days | Abiraterone Acetate | Placebo |
|---|---|---|
| Radiographic Progression-free Survival | 171.0 (169.0 to 192.0) | 110.0 (88.0 to 168.0) |
Collected over 5 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Abiraterone Acetate | — | 365/791 (46.1%) | 766/791 (96.8%) |
| Placebo | — | 175/394 (44.4%) | 381/394 (96.7%) |
| Placebo to Abiraterone Acetate | — | 29/67 (43.3%) | 57/67 (85.1%) |
| Event | Abiraterone Acetate | Placebo | Placebo to Abiraterone Acetate |
|---|---|---|---|
| Back painMusculoskeletal and connective tissue disorders | 12/791 | 11/394 | 4/67 |
| Spinal cord compressionNervous system disorders | 23/791 | 18/394 | 3/67 |
| PyrexiaGeneral disorders | 6/791 | 9/394 | 3/67 |
| PneumoniaInfections and infestations | 21/791 | 5/394 | 3/67 |
| Urinary tract infectionInfections and infestations | 19/791 | 3/394 | 3/67 |
| AnaemiaBlood and lymphatic system disorders | 26/791 | 15/394 | 1/67 |
| Bone painMusculoskeletal and connective tissue disorders | 16/791 | 13/394 | 1/67 |
| OsteonecrosisMusculoskeletal and connective tissue disorders | 2/791 | 0/394 | 2/67 |
| HydronephrosisRenal and urinary disorders | 12/791 | 3/394 | 2/67 |
| Disease progressionGeneral disorders | 12/791 | 2/394 | 2/67 |
| Event | Abiraterone Acetate | Placebo | Placebo to Abiraterone Acetate |
|---|---|---|---|
| FatigueGeneral disorders | 384/791 | 172/394 | 19/67 |
| Back painMusculoskeletal and connective tissue disorders | 282/791 | 138/394 | 23/67 |
| NauseaGastrointestinal disorders | 272/791 | 132/394 | 19/67 |
| ConstipationGastrointestinal disorders | 236/791 | 124/394 | 14/67 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 246/791 | 93/394 | 20/67 |
| Oedema peripheralGeneral disorders | 228/791 | 75/394 | 11/67 |
| Bone painMusculoskeletal and connective tissue disorders | 219/791 | 112/394 | 12/67 |
| AnaemiaBlood and lymphatic system disorders | 202/791 | 105/394 | 11/67 |
| VomitingGastrointestinal disorders | 204/791 | 97/394 | 14/67 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 170/791 | 81/394 | 13/67 |
| Age, Continuous(years) | Abiraterone Acetate | Placebo | Total |
|---|---|---|---|
| Mean | 69.1 ± 8.4 | 68.9 ± 8.61 | 69 ± 8.46 |
| Sex: Female, Male(Participants) | Abiraterone Acetate | Placebo | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 797 | 398 | 1195 |
| Region of Enrollment(participants) | Abiraterone Acetate | Placebo | Total |
|---|---|---|---|
| Australia | 69 | 35 | 104 |
| Austria | 11 | 1 | 12 |
| Belgium | 32 | 11 | 43 |
| Canada | 97 | 57 | 154 |
| France | 57 | 33 | 90 |
| Germany | 26 | 12 | 38 |
| Hungary | 5 | 2 | 7 |
| Italy | 21 | 12 | 33 |
| Netherlands | 4 | 2 | 6 |
| Republic of Ireland | 7 | 7 | 14 |
| Spain | 13 | 3 | 16 |
| United Kingdom | 119 | 61 | 180 |
| United States | 336 | 162 | 498 |
Showing the first 100 of 128 sites across 12 countries. Choose a country and city above to see the rest.
The record gives a start of May 2008, a primary completion of Aug 2010 and a completion of Oct 2012. It does not say whether these dates are actual or estimated.
Results were first posted in May 2013, 2 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Abiraterone Acetate